ExodusPoint Capital Management LP Increases Position in Omnicell, Inc. (NASDAQ:OMCL)

ExodusPoint Capital Management LP boosted its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 120.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 88,974 shares of the company’s stock after purchasing an additional 48,623 shares during the quarter. ExodusPoint Capital Management LP’s holdings in Omnicell were worth $3,961,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of OMCL. Vanguard Group Inc. lifted its position in shares of Omnicell by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 5,562,165 shares of the company’s stock valued at $247,628,000 after buying an additional 28,573 shares in the last quarter. Victory Capital Management Inc. raised its position in Omnicell by 32.9% during the fourth quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company’s stock worth $67,951,000 after acquiring an additional 377,883 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its holdings in Omnicell by 93.3% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company’s stock valued at $64,573,000 after purchasing an additional 699,925 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Omnicell by 0.3% in the third quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company’s stock valued at $48,176,000 after purchasing an additional 2,877 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Omnicell by 3.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 616,153 shares of the company’s stock worth $27,431,000 after purchasing an additional 21,157 shares in the last quarter. 97.70% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. JPMorgan Chase & Co. lowered their price objective on Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a report on Thursday, March 20th. Wells Fargo & Company lowered their price target on Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. StockNews.com downgraded Omnicell from a “buy” rating to a “hold” rating in a research note on Monday, March 24th. Benchmark reaffirmed a “buy” rating and set a $62.00 target price on shares of Omnicell in a research note on Tuesday, February 4th. Finally, Bank of America reduced their target price on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research report on Monday, January 6th. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $51.00.

Omnicell Stock Performance

NASDAQ OMCL opened at $32.69 on Monday. Omnicell, Inc. has a fifty-two week low of $25.12 and a fifty-two week high of $55.75. The firm has a market capitalization of $1.53 billion, a P/E ratio of 121.08, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78. The stock’s fifty day moving average is $38.16 and its two-hundred day moving average is $42.25. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. On average, research analysts anticipate that Omnicell, Inc. will post 1.09 earnings per share for the current year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.